Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
23595944
DOI
10.1136/jnnp-2012-304740
PII: jnnp-2012-304740
Knihovny.cz E-zdroje
- Klíčová slova
- Clinical Neurology, Mri, Multiple Sclerosis, Neurobiology, Neuroradiology,
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- časná lékařská intervence MeSH
- cholesterol krev MeSH
- demyelinizační nemoci krev farmakoterapie MeSH
- dospělí MeSH
- HDL-cholesterol krev MeSH
- index tělesné hmotnosti MeSH
- injekce intramuskulární MeSH
- interferon beta 1a MeSH
- interferon beta terapeutické užití MeSH
- kalcifediol krev MeSH
- kohortové studie MeSH
- kouření škodlivé účinky krev MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- magnetická rezonanční tomografie MeSH
- mladý dospělý MeSH
- mozek účinky léků patologie MeSH
- prospektivní studie MeSH
- roztroušená skleróza krev diagnóza farmakoterapie MeSH
- thyreotropin krev MeSH
- thyroxin krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- cholesterol MeSH
- HDL-cholesterol MeSH
- interferon beta 1a MeSH
- interferon beta MeSH
- kalcifediol MeSH
- LDL-cholesterol MeSH
- thyreotropin MeSH
- thyroxin MeSH
OBJECTIVES: To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were obtained in pretreatment serum from 135 high risk patients with CIS (≥ 2 brain MRI lesions and ≥ 2 oligoclonal bands) enrolled in the Observational Study of Early Interferon β-1a Treatment in High Risk Subjects after CIS study (SET study), which prospectively evaluated the effect of intramuscular interferon β-1a treatment following the first demyelinating event. Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status and body mass index were also obtained. Clinical and MRI assessments were obtained within 4 months of the initial demyelinating event and at 6, 12 and 24 months. RESULTS: The time to first relapse and number of relapses were not associated with any of the lipid profile variables. Higher LDL-C (p=0.006) and TC (p=0.001) levels were associated with increased cumulative number of new T2 lesions over 2 years. Higher free thyroxine levels were associated with lower cumulative number of contrast-enhancing lesions (p=0.008). Higher TC was associated as a trend with lower baseline whole brain volume (p=0.020). Higher high density lipoprotein was associated with higher deseasonalised 1,25-dihydroxy vitamin D3 (p=0.003) levels and a trend was found for deseasonalised 25-hydroxy vitamin D3 (p=0.014). CONCLUSIONS: In early multiple sclerosis, lipid profile variables particularly LDL-C and TC levels are associated with inflammatory MRI activity measures.
Citace poskytuje Crossref.org
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
MRI correlates of disability progression in patients with CIS over 48 months
